Letters to the Editor

The British Heart Journal welcomes letters commenting on papers that it has published within the past six months.

All letters must be typed with double spacing and signed by all authors.

No letter should be more than 600 words.

In general, no letter should contain more than six references (also typed with double spacing).

Endothelium in control

Sir,—In his St Cyres Lecture (British Heart Journal 1990;65:116-25) Professor A H Henderson states that the half life of endothelin derived relaxing factor (EDRF) nitric oxide is "likely to be less than a second in vivo" and that "each millimetre of endothelium controls its little bit of the vascular system." I believe it is possible to place these suggestions on a more precise basis. In the picomolar concentrations of nitric oxide secreted by endothelium the half life of the reaction between nitric oxide and oxygen is far too slow to account for this proposed rapid removal. By contrast the rate of removal by haem groups is exceedingly rapid and the second order rate constant for reaction of nitric oxide with the red cell is 167 1 mmol⁻¹ s⁻¹ in vitro. There is growing evidence that this value may be applied to blood nitric oxide uptake in vivo at least in human pulmonary capillaries. Though the rate of reaction of nitric oxide with oxyhaemoglobin in vitro is about 250 times as fast as the reaction with the red cell, because less than 0.03% of the haemoglobin in blood is in the free form, the reaction with the red cell is quantitatively more important. Similar arguments apply to tissue haem groups and also superoxide ion. The half life of nitric oxide in blood is obtained as follows:

\[
\frac{1}{2} = \frac{0.693}{(167 \times 9)} = 4.6 \times 10^4 \text{ seconds}
\]

where 0.693 is ln 2, 167 is the second order rate constant (see above), and 9 is the concentration of Hb in mmol/l corresponding to a haemoglobin concentration of 14.6 g/dl. The distance travelled in one half life is obtained as the velocity of blood flow (1 m/s in the aorta during systole, 0.3 m/s in the venous cava, 5.10⁻⁴ m/s in a capillary) multiplied by \( t \frac{1}{2} \): that is, 4.6 \times 10⁻¹ m in the aorta, 1.4 \times 10⁻¹ m in the vena cava, and 2 \times 10⁻¹ m in capillary. The half life of nitric oxide in blood in vivo can be seen to be exceedingly short and the distance "downstream" over which a section of endothelium can have an influence extremely small especially in the capillary.

COLIN BORLAND
Department of Medicine, Hitchinbrooke Hospital, Huntingdon, Cambridgeshire PE18 8NT

1 Austin AT. The chemistry of the higher oxides of nitrogen as related to the manufacture, storage and administration of nitric oxide. Dr J Pharmacol (1967) 134:9-25.


This letter was shown to the author, who replies as follows:

Sir,—I am grateful to Dr Borland for his interest and for the quantitative pyramides he builds on my point which was simply to emphasise the very localised nature of vasodilatation mediated by EDRF.

The half life of EDRF is documented as being in the order of seconds by bioassay of oxygenated effluent buffer from endothelialised artery segments. Nitric oxide oxidation in aqueous buffer is related to po2 but is some 30 times faster in transit through perfused hearts where its half life was shown to be about 0.1 s. This is consistent with previously reported evidence that the intramural dilator signal in the anaesthesised dog femoral artery was localised to within 1 cm. Clearly the presence of haemoglobin (which has about 1500 times greater affinity for nitric oxide than for carbon monoxide) will further reduce the half life of nitric oxide within the vascular compartment in vivo. Small amounts of "free" haemoglobin are in fact complexed to haptoglobin in circulating blood (< 0.03%) of total haemoglobin in the blood, as Dr Borland states), accounting for the variable EDRF-inhibiting activity of plasma (the inhibitory activity in samples from some of our human volunteers was unusually high, and after appropriate experimentation this was attributed to alcohol intake). The largest sink of haemoglobin is indeed within the erythrocytes, whose EDRF inhibitory activity we found to be that of similar concentrations of free haemoglobin, as expected from the lipid solubility of nitric oxide and its ready passage through red cell membranes. Superoxide anions, widely present in biological systems, further shorten the half life of nitric oxide (rate constant of the reaction NO + O₂⁻ at physiological pH, k = 3.7 \times 10⁻¹ M⁻¹ s⁻¹). The concentration of oxygen free radicals is likely to vary within the rather pathological conditions. Recent evidence suggests, for example, that the reduced EDRF activity shown in experimental hypercholaemia may be due to EDRF inactivation rather than decreased production, on the basis of a decrease in bioassayed dilator activity but an increase in nitric oxide production when measured by chemiluminescence, the decrease in activity being attributable to the superoxide anion production beneath atheromatous plaques.

Biologically, let alone pathology (and perhaps alcohol), clearly introduces complexity. I think we agree though that locally released EDRF has little downstream activity.

A H HENDERSON
Department of Cardiology, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN


8 Nakamura M, Tagawa H, Tomaiko H. Reduced release of EDRF and significant inactivation of EDRF at the tunica media beneath the atheromatous plaque in aorta of WHHL rabbits [abstr]. Arch Int Pharmacodyn 1990; 385:209.

Novel exercise protocol suitable for use on a treadmill or a bicycle ergometer

Sir,—The standardisation of exercise tests is now a major issue and the Working Group on Exercise Testing of the European Society of Cardiology has organised a symposium to examine this problem. In November 1990 Dr Northbridge and colleagues (British Heart Journal 1990;64:313-6) presented data on a new exercise protocol that is based on exponential (rather than linear) increments in workload. In their experience the rise in oxygen consumption (ml/kg/min) is very similar whether the test is performed on a bicycle or on a treadmill; also they mention that the highest stage required to test even relatively fit patients is reached after 15 minutes. We have tested prospectively and randomly these new protocols in 13 healthy men (mean age 33, range 25-49; mean weight 80, range 62-115 kg) and our data (fig 1) indicate that oxygen consumption was significantly greater (unpaired t test; p < 0.05) during the last nine minutes of exercise on the standardised exponential exercise protocol (STEEP). The heart rates were also greater (p < 0.05) with the bicycle protocol during the last six minutes of the exercise than when the treadmill protocol was used. All the subjects were able to perform the 15 minutes of the STEEP treadmill test while only six were able to reach the fifteenth minute of the bicycle protocol; at the fifteenth minute of the STEEP bicycle test, all patients complained of pain in the legs, a symptom that was almost absent at the fifteenth minute of the STEEP treadmill test. Also the reason for interrupting the STEEP bicycle test was always muscle fatigue or pain. These observations about heart rate and exercise duration are very similar to those made by Northbridge et al.

The explanation for our different results remains unclear. In our experience, we think that for the heaviest subjects the final increases in workload of the bicycle protocol are too large (from 25 to 40 w/min) to be tolerated by the leg muscles and that muscle soreness becomes the major limiting factor. Because of the differences in oxygen consumption and workload between these two protocols, these new STEEP tests are not the answer to our growing need for standardised exercise tests that can be used on both the treadmill

Br Heart J 1991;66:405-7

Br Heart J: first published as 10.1136/hrt.66.5.405-a on 1 November 1991. Downloaded from http://heart.bmj.com/ on June 3, 2020 by guest. Protected by copyright.